TrialPharmacoEconomics2021

Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland.

Nadine Schur et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.